Results for tag: "Diabetic Macular Edema"

Diabetic macular edema (DME) is a complication of diabetes caused by fluid accumulation in the macula, the central part of the retina responsible for sharp vision. In the optical context, DME represents a serious threat to visual acuity and can lead to legal blindness if left untreated. The market for DME treatments consists of both pharmacological interventions and laser surgery. Pharmacological treatments typically involve intraocular injections of anti-VEGF agents, corticosteroids, or a combination of both to reduce inflammation and prevent leakage from blood vessels. Laser photocoagulation therapy is another treatment option that uses focused light to seal off leaking vessels in the retina. Medical devices specifically designed for the diagnosis and monitoring of DME include optical coherence tomography (OCT) scanners and fundus cameras, which are integral in assessing the progression of the disease and the effectiveness of treatments. These technologies have evolved to provide high-resolution imaging of retinal structures, facilitating early diagnosis and intervention. Together, pharmacological, surgical, and diagnostic approaches constitute a comprehensive market catering to the therapeutic and monitoring needs of DME patients within the optical healthcare sector. Several companies are active in the DME market, including Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Allergan. These companies provide various treatments and devices for managing Dermal Macular Edema, each bringing their expertise and innovation to address the challenges posed by this vision-threatening condition. Show Less Read more